<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Glatiramer acetate: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Glatiramer acetate: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Glatiramer acetate: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="12509" href="/d/html/12509.html" rel="external">see "Glatiramer acetate: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F176076"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Copaxone;</li>
<li>Glatopa</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52867042"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Copaxone;</li>
<li>Glatect</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F176098"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Biological, Miscellaneous</li></ul></div>
<div class="block doa drugH1Div" id="F176078"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note: Safety:</b> In high-risk populations or in countries with high tuberculosis burden, screen for latent infections (eg, hepatitis, tuberculosis) prior to initiating therapy. For patients who screen positive for latent infections, consult infectious disease or other appropriate specialists (eg, liver specialists) regarding treatment options before initiating therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31462584']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31462584'])">Ref</a></span>). <b>Dosage forms: </b>Glatiramer 20 mg/mL and 40 mg/mL formulations are not interchangeable.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="800e2fc1-5444-4538-baf2-520898316bf7">Multiple sclerosis, relapsing</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Multiple sclerosis, relapsing:</b>
<b>SUBQ:</b> 20 mg once daily or 40 mg 3 times per week administered at least 48 hours apart.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991636"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block doha drugH1Div" id="F50988929"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doe drugH1Div" id="F176079"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F176057"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions were generally less common in trials with patients treated with 40 mg per mL three times per week than in trials with patients treated with 20 mg per mL per day.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Chest pain (2% to 13%), vasodilation (3% to 20%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash (2% to 19%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea (2% to 15%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Type I hypersensitivity reaction (2% to 16%; postinjection)</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Development of IgG antibodies (3 months: ≥3 x baseline: 80%; 12 months: greater than baseline: 90%; ≥3 x baseline: 30%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Infection (30%), influenza (14%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Erythema at injection site (22% to 43%), itching at injection site (6% to 27%), pain at injection site (10% to 40%), residual mass at injection site (6% to 26%), swelling at injection site (6% to 19%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Anxiety (13%), pain (20%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Asthenia (22%), back pain (12%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dyspnea (3% to 14%), nasopharyngitis (11%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Edema (8%), facial edema (3%), palpitations (9%), peripheral edema (3%), syncope (3%), tachycardia (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Erythema of skin (2%), hyperhidrosis (7%), pruritus (5%), urticaria (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Weight gain (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Dysphagia (2%), gastroenteritis (6%), vomiting (7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urinary urgency (5%), vulvovaginal candidiasis (4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Benign skin neoplasm (2%), lymphadenopathy (7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Atrophy at injection site (≤2%), fibrosis at injection site (2%), hypersensitivity reaction at injection site (4%), inflammation at injection site (2% to 9%), lipoatrophy at injection site (≤2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Chills (2% to 3%), migraine (4%), nervousness (2%), speech disturbance (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Laryngospasm (2%), tremor (4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Diplopia (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchitis (6%), cough (6%), flu-like symptoms (3%), rhinitis (7%), viral respiratory tract infection (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (3% to 6%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Thrombocytopenia</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Herpes simplex infection</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Acute myocardial infarction, angina pectoris, cardiac arrhythmia, cardiac failure, cardiomegaly, cardiomyopathy, cerebrovascular accident, coronary occlusion, deep vein thrombophlebitis, pericardial effusion, peripheral vascular disease, pulmonary embolism, thrombosis</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypercholesterolemia</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Cholelithiasis, enlargement of abdomen, eructation, gastrointestinal hemorrhage, gastrointestinal ulcer</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Nephrosis, urinary frequency</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Acute leukemia, bladder carcinoma, breast carcinoma, CNS neoplasm, genitourinary neoplasm, lung carcinoma, ovarian carcinoma, pseudolymphoma</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatic cirrhosis, hepatic failure, hepatic injury, hepatitis, jaundice</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Nonimmune anaphylaxis, tongue edema</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Sepsis</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Tissue necrosis at injection site</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Abnormal dreams, aphasia, brain edema, hydrocephalus, meningitis, neuralgia, seizure</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Muscle spasm, myelitis, rheumatoid arthritis, systemic lupus erythematosus</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Glaucoma</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Renal failure syndrome</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Pleural effusion</p></div>
<div class="block coi drugH1Div" id="F176068"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to glatiramer acetate, mannitol, or any component of the formulation</p></div>
<div class="block war drugH1Div" id="F176054"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Chest pain: May or may not occur with the immediate postinjection reaction; described as a transient pain usually resolving in a few minutes; often unassociated with other symptoms. Episodes usually begin ≥1 month after initiation of treatment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic toxicity: Liver failure and hepatitis with jaundice (sometimes severe) have occurred from days to years after initiation of therapy; consider discontinuation of therapy if signs and symptoms occur.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity reactions: Anaphylactoid reactions (rare) have been reported.</p>
<p style="text-indent:-2em;margin-left:4em;">• Immune response: Although there has not been a systematic evaluation of glatiramer’s potential to affect other immune functions, it may interfere with recognition of foreign antigens undermining the body's tumor surveillance and defense system against infection.</p>
<p style="text-indent:-2em;margin-left:4em;">• Infections: In high-risk populations or in countries with high tuberculosis burden, screen for latent infections (eg, hepatitis, tuberculosis) prior to initiating therapy. For patients who screen positive for latent infections, consult infectious disease or other specialists (eg, liver specialists) regarding treatment options before initiating therapy (AAN [Farez 2019]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Lipoatrophy: May occur locally at injection site at various times after treatment (sometimes after several months) and may not resolve; to possibly minimize occurrence, advise patients to follow proper injection technique and rotate site with each injection. Skin necrosis has also been observed.</p>
<p style="text-indent:-2em;margin-left:4em;">• Systemic reactions: Postinjection systemic reactions may occur immediately (within seconds to minutes of injection; majority of reactions observed within 1 hour) and in a substantial percentage of patients (~16% [20 mg/mL] and ~2% [40 mg/mL] in studies); symptoms (anxiety, chest pain, constriction of the throat, dyspnea, flushing, palpitations, tachycardia, urticaria) are usually self-limited and transient. These symptoms generally occur several months after initiation of treatment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Antigenic: Glatiramer acetate is antigenic and may possibly lead to the induction of untoward host responses. Glatiramer acetate-reactive antibodies (IgG subtype) form in most patients.</p>
<p style="text-indent:-2em;margin-left:4em;">• Immunizations: Avoid live-attenuated vaccines in patients who currently receive or have recently discontinued glatiramer acetate; consider using live-attenuated vaccines only if risk of infection is high and killed vaccines are unavailable (AAN [Farez 2019]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Medication errors: Administering glatiramer acetate products with incompatible autoinjectors may cause medication errors (eg, partial dose, dose omission); not all glatiramer acetate products have marketed optional compatible autoinjectors. Prior to using an optional autoinjector, ensure the device is compatible for use with the specific glatiramer acetate product by referring to autoinjector labeling; availability of compatible autoinjectors may change over time.</p></div>
<div class="block foc drugH1Div" id="F176063"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Prefilled Syringe, Subcutaneous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Copaxone: 20 mg/mL (1 mL); 40 mg/mL (1 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Glatopa: 20 mg/mL (1 mL) [contains mannitol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Glatopa: 40 mg/mL (1 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Prefilled Syringe, Subcutaneous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 20 mg/mL (1 mL); 40 mg/mL (1 mL)</p></div>
<div class="block geq drugH1Div" id="F176050"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F176069"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution Prefilled Syringe</b> (Copaxone Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg/mL (per mL): $284.56</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg/mL (per mL): $583.20</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution Prefilled Syringe</b> (Glatiramer Acetate Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg/mL (per mL): $216.41</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg/mL (per mL): $524.30</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution Prefilled Syringe</b> (Glatopa Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg/mL (per mL): $216.41</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg/mL (per mL): $524.30</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52867043"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Prefilled Syringe, Subcutaneous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Copaxone: 20 mg/mL (1 ea, 1 mL); 40 mg/mL (1 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Glatect: 20 mg/mL (1 mL)</p></div>
<div class="block adm drugH1Div" id="F176065"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>SUBQ:</b> For SUBQ administration in the arms, abdomen, hips, or thighs using prefilled syringe or an optional compatible injection device; rotate injection sites to possibly minimize the occurrence of lipoatrophy. Do not administer IV. Administer the 40 mg dose on the same 3 days each week (eg, Monday, Wednesday, Friday) at least 48 hours apart. Allow syringe to stand at room temperature for 20 minutes prior to injection. Discard unused portions. If using an optional autoinjector, ensure device is compatible with Copaxone or Glatopa; using a noncompatible device may increase the risk of medication errors; refer to autoinjector instructions for additional details.</p></div>
<div class="block use drugH1Div" id="F176064"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Multiple sclerosis, relapsing:</b> Treatment of relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.</p></div>
<div class="block mst drugH1Div" id="F176105"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Copaxone may be confused with Compazine</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes that have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299405"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F6220654"><span class="drugH1">Drug Interactions</span>
<br/><br/><div class="clear"></div><p style="text-indent:0em;display:inline">There are no known significant interactions.</p></div>
<div class="block rep_considerations drugH1Div" id="F53487266"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;display:inline">In general, disease-modifying therapies for multiple sclerosis (MS) are stopped prior to a planned pregnancy, except in females at high risk of MS activity (AAN [Rae-Grant 2018]). When disease-modifying therapy is needed in patients planning to become pregnant (eg, high risk of disease reactivation), glatiramer acetate may be considered until pregnancy is confirmed. Delaying pregnancy is recommended for females with persistent high disease activity (ECTRIMS/EAN [Montalban 2018]).</p></div>
<div class="block pri drugH1Div" id="F176070"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Outcome data following maternal use of glatiramer acetate in pregnancy are available (Fragoso 2014; Herbstritt 2016; Kaplan 2022; MacDonald 2019; Nguyen 2019; Sandberg-Wollheim 2018).</p>
<p style="text-indent:0em;margin-top:2em;">In general, disease-modifying therapies for multiple sclerosis (MS) are not initiated during pregnancy, except in females at high risk of MS activity (AAN [Rae-Grant 2018]). When disease-modifying therapy is needed in females planning a pregnancy (eg, high risk of disease reactivation), glatiramer acetate may be considered until pregnancy is confirmed, and in select cases (eg, women with active disease), use may be continued during pregnancy (ECTRIMS/EAN [Montalban 2018]).</p></div>
<div class="block brc drugH1Div" id="F16265835"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if glatiramer acetate is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Outcome data following use of glatiramer acetate in lactating patients are available (Ines Ciplea 2022; Kaplan 2022).</p>
<p style="text-indent:-2em;margin-left:2em;">Breastfeeding is not expected to provide clinically relevant exposure to an infant via breast milk. According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and the benefits of treatment to the mother. Based on its chemical properties, others consider glatiramer acetate compatible with breastfeeding (Almas 2016; Dobson 2019; Fragoso 2018).</p></div>
<div class="block mop drugH1Div" id="F55430639"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Latent infection screening (eg, hepatitis, tuberculosis) in high-risk populations or in countries with high tuberculosis burden (baseline).</p></div>
<div class="block pha drugH1Div" id="F176053"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Glatiramer is a mixture of random polymers of four amino acids; L-alanine, L-glutamic acid, L-lysine, and L-tyrosine, the resulting mixture is antigenically similar to myelin basic protein, which is an important component of the myelin sheath of nerves; glatiramer is thought to induce and activate T-lymphocyte suppressor cells specific for a myelin antigen, it is also proposed that glatiramer interferes with the antigen-presenting function of certain immune cells opposing pathogenic T-cell function</p></div>
<div class="block phk drugH1Div" id="F176067"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: Small amounts of intact and partial hydrolyzed drug enter lymphatic circulation.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: SUBQ: Large percentage hydrolyzed locally.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F176071"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Galtipex</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Copaxone | Escadra | Polimunol</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Copaxone | Perscleran</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Copaxone | Glatira | Glatiramer acetate teva</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Copaxone | Glataxon | Glatiramyl</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Copaxone | Remurel</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Copaxone</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Copaxone | Glatiramyl</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Copaxone</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Autix | Copaxone | Glamatir | Glatir | Glystral</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Copaxone | Remurel</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Clift | Copaxone | Glatirameracetate abz</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Probioglat</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Copaxone | Remurel | Remurel zentiva</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Copaxone | Glatiramero mylan</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Copaxone | Glatimyl</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Copaxone | Glatiramer mylan</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Brabio | Copaxone</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Clift | Copaxone | Glatiramer/mylan</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Copaxone | Glatirameracetat Pliva | Remurel</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Copaxone | Remurel</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Brabio | Copaxone</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Glatira</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Copaxone | Copemyl | Copemyltri</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Copaxone</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Copaxone</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Galtipex</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Copaxone | Remurel</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Copaxone</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Copaxone | Remurel</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Copaxone | Doxelev | Linator | Prig | Probioglat | Tlenec</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Copaxone | Glatirameeracetat</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Copaxone | Copemyl</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Copaxone</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Copaxone</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Remurel</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Copaxone | Glatopa</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Acetato de glatiramero mylan | Clift | Copaxone</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Copaxone | Glamatir | Glatiramer libra</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Copaxone | Remurel</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Aksoglatiran fs | Copaxone | Copaxone teva | Glatirat | Timexon</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Glatiject | Glitaxon</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Copaxone</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Copaxone</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Copaxone | Remurel</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Glitaxon</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Copaxone</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Copaxone | Glatiramer acetat-vista</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-26966579">
<a name="26966579"></a>Almas S, Vance J, Baker T, Hale T. Management of multiple sclerosis in the breastfeeding mother. <i>Mult Scler Int</i>. 2016;2016:6527458. doi: 10.1155/2016/6527458.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glatiramer-acetate-drug-information/abstract-text/26966579/pubmed" id="26966579" target="_blank">26966579</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3302705">
<a name="3302705"></a>Bornstein MB, Miller A, Slagle S, et al. A Pilot Trial of Cop 1 in Exacerbating-Remitting Multiple Sclerosis. <i>N Engl J Med.</i> 1987;317(7):408-414.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glatiramer-acetate-drug-information/abstract-text/3302705/pubmed" id="3302705" target="_blank">3302705</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17372130">
<a name="17372130"></a>Cohen JA, Rovaris M, Goodman AD, et al. Randomized, Double-Blind, Dose-Comparison Study of Glatiramer Acetate in Relapsing-Remitting MS. <i>Neurology.</i> 2007;68(12):939-944.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glatiramer-acetate-drug-information/abstract-text/17372130/pubmed" id="17372130" target="_blank">17372130</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11261502">
<a name="11261502"></a>Comi G, Filippi M, Wolinsky JS, et al. European/Canadian Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of the Effects of Glatiramer Acetate on Magnetic Resonance Imaging-Measured Disease Activity and Burden in Patients With Relapsing Multiple Sclerosis. <i>Ann Neurol.</i> 2001;49(3):290-297.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glatiramer-acetate-drug-information/abstract-text/11261502/pubmed" id="11261502" target="_blank">11261502</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19815268">
<a name="19815268"></a>Comi G, Martinelli V, Rodegher M, et al; PreCISe study group. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial [published correction appears in <i>Lancet</i>. 2010;375(9724):1436]. <i>Lancet</i>. 2009;374(9700):1503-1511. doi: 10.1016/S0140-6736(09)61259-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glatiramer-acetate-drug-information/abstract-text/19815268/pubmed" id="19815268" target="_blank">19815268</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Copaxone.1">
<a name="Copaxone.1"></a>Copaxone (glatiramer acetate) [prescribing information]. Parsippany, NJ: Teva Neuroscience Inc; November 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22840794">
<a name="22840794"></a>Coyle PK. Pregnancy and multiple sclerosis. <i>Neurol Clin</i>. 2012;30(3):877-888.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glatiramer-acetate-drug-information/abstract-text/22840794/pubmed" id="22840794" target="_blank">22840794</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30612100">
<a name="30612100"></a>Dobson R, Dassan P, Roberts M, Giovannoni G, Nelson-Piercy C, Brex PA. UK consensus on pregnancy in multiple sclerosis: 'Association of British Neurologists' guidelines. <i>Pract Neurol</i>. 2019;19(2):106-114. doi: 10.1136/practneurol-2018-002060.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glatiramer-acetate-drug-information/abstract-text/30612100/pubmed" id="30612100" target="_blank">30612100</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31462584">
<a name="31462584"></a>Farez MF, Correale J, Armstrong MJ, et al. Practice guideline update summary: vaccine-preventable infections and immunization in multiple sclerosis: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. <i>Neurology</i>. 2019;93(13):584-594. doi:10.1212/WNL.0000000000008157<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glatiramer-acetate-drug-information/abstract-text/31462584/pubmed" id="31462584" target="_blank">31462584</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25176273">
<a name="25176273"></a>Fragoso YD. Glatiramer acetate to treat multiple sclerosis during pregnancy and lactation: a safety evaluation. <i>Expert Opin Drug Saf</i>. 2014;13(12):1743-1748.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glatiramer-acetate-drug-information/abstract-text/25176273/pubmed" id="25176273" target="_blank">25176273</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30167914">
<a name="30167914"></a>Fragoso YD, Adoni T, Brooks JBB, et al. Practical evidence-based recommendations for patients with multiple sclerosis who want to have children. <i>Neurol Ther</i>. 2018;7(2):207-232. doi: 10.1007/s40120-018-0110-3.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glatiramer-acetate-drug-information/abstract-text/30167914/pubmed" id="30167914" target="_blank">30167914</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sandoz.1">
<a name="Sandoz.1"></a>Glatopa (glatiramer acetate) [prescribing information]. Princeton, NJ: Sandoz Inc; March 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26754804">
<a name="26754804"></a>Herbstritt S, Langer-Gould A, Rockhoff M, et al. Glatiramer acetate during early pregnancy: a prospective cohort study. <i>Mult Scler</i>. 2016;22(6):810-816. doi: 10.1177/1352458515623366.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glatiramer-acetate-drug-information/abstract-text/26754804/pubmed" id="26754804" target="_blank">26754804</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35362346">
<a name="35362346"></a>Ines Ciplea A, Kurzeja A, Thiel S, et al. Eighteen-month safety analysis of offspring breastfed by mothers receiving glatiramer acetate therapy for relapsing multiple sclerosis - COBRA study. <i>Mult Scler</i>. 2022:13524585221083982. doi:10.1177/13524585221083982<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glatiramer-acetate-drug-information/abstract-text/35362346/pubmed" id="35362346" target="_blank">35362346</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7617181">
<a name="7617181"></a>Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 Reduced Relapse Rate and Improves Disability in Relapsing-Remitting Multiple Sclerosis: Results of a Phase III Multicenter, Double-Blind, Placebo-Controlled Trial. <i>Neurology.</i> 1995;45(7):1268-1276.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glatiramer-acetate-drug-information/abstract-text/7617181/pubmed" id="7617181" target="_blank">7617181</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9521260">
<a name="9521260"></a>Johnson KP, Brooks BR, Cohen JA, et al. Extended Use of Glatiramer Acetate (Copaxone) is Well Tolerated and Maintains Its Clinical Effect on Multiple Sclerosis Relapse Rate and Degree of Disability. <i>Neurology.</i> 1998;50(3):701-708.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glatiramer-acetate-drug-information/abstract-text/9521260/pubmed" id="9521260" target="_blank">9521260</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35297004">
<a name="35297004"></a>Kaplan S, Zeygarnik M, Stern T. Pregnancy, fetal, and infant outcomes following maternal exposure to glatiramer acetate during pregnancy and breastfeeding. <i>Drug Saf</i>. 2022;45(4):345-357. doi:10.1007/s40264-022-01168-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glatiramer-acetate-drug-information/abstract-text/35297004/pubmed" id="35297004" target="_blank">35297004</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23448215">
<a name="23448215"></a>Lu E, Wang BW, Guimond C, et al. Safety of disease-modifying drugs for multiple sclerosis in pregnancy: current challenges and future considerations for effective pharmacovigilance. <i>Expert Rev Neurother</i>. 2013;13(3):251-260.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glatiramer-acetate-drug-information/abstract-text/23448215/pubmed" id="23448215" target="_blank">23448215</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30834654">
<a name="30834654"></a>MacDonald SC, McElrath TF, Hernández-Díaz S. Use and safety of disease-modifying therapy in pregnant women with multiple sclerosis. <i>Pharmacoepidemiol Drug Saf</i>. 2019;28(4):556-560. doi: 10.1002/pds.4735.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glatiramer-acetate-drug-information/abstract-text/30834654/pubmed" id="30834654" target="_blank">30834654</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29352526">
<a name="29352526"></a>Montalban X, Gold R, Thompson AJ, et al. ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis [published correction appears in <i>Eur J Neurol</i>. 2018;25(3):605]. <i>Eur J Neurol</i>. 2018;25(2):215-237. doi: 10.1111/ene.13536.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glatiramer-acetate-drug-information/abstract-text/29352526/pubmed" id="29352526" target="_blank">29352526</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30623864">
<a name="30623864"></a>Nguyen AL, Havrdova EK, Horakova D, et al; MSBase Study Group. Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: a contemporary cohort study. <i>Mult Scler Relat Disord</i>. 2019;28:235-243. doi: 10.1016/j.msard.2019.01.003.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glatiramer-acetate-drug-information/abstract-text/30623864/pubmed" id="30623864" target="_blank">30623864</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11006371">
<a name="11006371"></a>Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple Sclerosis. <i>N Engl J Med.</i> 2000;343(13):938-952.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glatiramer-acetate-drug-information/abstract-text/11006371/pubmed" id="11006371" target="_blank">11006371</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Rae.1">
<a name="Rae.1"></a>Rae-Grant A, Day GS, Marrie RA, et al. Practice guideline: disease-modifying therapies for adults with multiple sclerosis: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. https://download.lww.com/wolterskluwer_vitalstream_com/PermaLink/WNL/A/WNL_2018_04_19_RAEGRANT_NEUROLOGY2017835181R1_SDC3.pdf. Published April 2018. Accessed March 20, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29507538">
<a name="29507538"></a>Sandberg-Wollheim M, Neudorfer O, Grinspan A, et al. Pregnancy outcomes from the branded glatiramer acetate pregnancy database. <i>Int J MS Care</i>. 2018;20(1):9-14. doi: 10.7224/1537-2073.2016-079.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glatiramer-acetate-drug-information/abstract-text/29507538/pubmed" id="29507538" target="_blank">29507538</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 8490 Version 210.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
